Plerixafor (AMD3100) induces prolonged mobilization of acute lymphoblastic leukemia cells and increases the proportion of cycling cells in the blood in mice

Experimental Hematology

Volumn 41, Issue 3, 2013, Pages

  Welschinger, Robert ^a   Liedtke, Florian ^b   Basnett, Jordan ^a   Dela Pena, Aileen ^a   Juarez, Julius G ^a   Bradstock, Kenneth F ^c   Bendall, Linda J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF APPLIED SCIENCES   (Germany)

^c WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; DOXORUBICIN; PLERIXAFOR; STROMAL CELL DERIVED FACTOR 1; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGICAL THERAPY; BLOOD TOXICITY; CHEMOTAXIS; CONTROLLED STUDY; DRUG POTENTIATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; LEUKEMIC CELL MOBILIZATION; MOUSE; NONHUMAN; OSMOTIC PUMP; OVERALL SURVIVAL; PRIORITY JOURNAL; SPLEEN; TUMOR XENOGRAFT;

EID: 84874965345     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2012.11.004     Document Type: Article

References (31)

1. Moricke A., Zimmermann M., Reiter A., et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 2010, 24:265-284.
2. Gokbuget N., Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Semin Hematol 2009, 46:64-75.
3. Tavernier E., Boiron J., Huguet F., et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia 2007, 21:1907-1914.
4. Manabe A., Coustan-Smith E., Behm F., Raimondi S., Campana D. Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia. Blood 1992, 79:2370-2377.
5. Lapidot T., Ponomaryov T., Petit I., et al. The chemokine SDF-1 is produced in the bone marrow mainly by osteoblast, bone forming cells. Increased production following total body irradiation, and cyclophosphamide. American Society of Hematology 1999, 690a. W.B. Saunders, New Orleans. K. Kaushanski (Ed.).
6. Makrynikola V., Bradstock K. Adhesion of precursor-B acute lymphoblastic leukaemia cells to bone marrow stromal proteins. Leukemia 1993, 7:86-92.
7. Messinger Y., Chelstrom L., Gunther R., Uckun F. Selective homing of human leukemic B-cell precursors to specific lymphohematopoietic microenvironments in SCID mice: A role for the beta 1 integrin family surface adhesion molecules VLA-4 and VLA-5. Leuk Lymphoma 1996, 23:61-69.
8. Papayannopoulou T., Craddock C., Nakamoto B., Priestley G.V., Wolf N.S. The VLA4/VCAM-1 adhesion pathway defines contrasting mechanisms of lodgement of transplanted murine hemopoietic progenitors between bone marrow and spleen. Proc Natl Acad Sci USA 1995, 92:9647-9651.
9. Avigdor A., Goichberg P., Shivtiel S., et al. CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. Blood 2004, 103:2981-2989.
10. Konopleva M., Konoplev S., Hu W., Zaritskey A., Afanasiev B., Andreeff M. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 2002, 16:1713-1724.
11. Mudry R.E., Fortney J.E., York T., Hall B.M., Gibson L.F. Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy. Blood 2000, 96:1926-1932.
12. Juarez J., Bradstock K., Gottlieb D., Bendall L. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia 2003, 17:1294-1300.
13. Nervi B., Ramirez P., Rettig M.P., et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 2009, 113:6206-6214.
14. Juarez J., Dela Pena A., Baraz R., et al. CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment. Leukemia 2007, 21:1249-1257.
15. Peled A., Petit I., Kollet O., et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999, 283:845-848.
16. Liles W., Broxmeyer H., Rodger E., et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003, 102:2728-2730.
17. Flomenberg N., Devine S., Dipersio J., et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005, 106:1867-1874.
18. Lataillade J., Clay D., Dupuy C., et al. Chemokine SDF-1 enhances circulating CD34(+) cell proliferation in synergy with cytokines: possible role in progenitor survival. Blood 2000, 95:756-768.
19. Crazzolara R., Cisterne A., Thien M., et al. Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia. Blood 2009, 113:3297-3306.
20. Gaundar S.S., Bradstock K.F., Bendall L.J. p38MAPK inhibitors attenuate cytokine production by bone marrow stromal cells and reduce stroma-mediated proliferation of acute lymphoblastic leukemia cells. Cell Cycle 2009, 8:2975-2983.
21. Mihara K., Imai C., Coustan-Smith E., et al. Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase. Br J Haematol 2003, 120:846-849.
22. Bendall L.J., Baraz R., Juarez J., Shen W., Bradstock K.F. Defective p38 mitogen-activated protein kinase signaling impairs chemotaxic but not proliferative responses to stromal-derived factor-1alpha in acute lymphoblastic leukemia. Cancer Res 2005, 65:3290-3298.
23. Matsunaga T., Takemoto N., Sato T., et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 2003, 9:1158-1165.
24. Tassone P., Neri P., Burger R., et al. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Clin Cancer Res 2005, 11:4251-4258.
25. Dierks C., Grbic J., Zirlik K., et al. Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med 2007, 13:944-951.
26. Broxmeyer H., Orschell C., Clapp D., et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005, 201:1307-1318.
27. Scott M.A., Apperley J.F., Bloxham D.M., et al. Biological properties of peripheral blood progenitor cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor. Br J Haematol 1997, 97:474-480.
28. Williams C.D., Linch D.C., Watts M.J., Thomas N.S. Characterization of cell cycle status and E2F complexes in mobilized CD34+ cells before and after cytokine stimulation. Blood 1997, 90:194-203.
29. Bonig H., Chudziak D., Priestley G., Papayannopoulou T. Insights into the biology of mobilized hematopoietic stem/progenitor cells through innovative treatment schedules of the CXCR4 antagonist AMD3100. Exp Hematol 2009, 37:402-415 e401.
30. Nie Y., Han Y.C., Zou Y.R. CXCR4 is required for the quiescence of primitive hematopoietic cells. J Exp Med 2008, 205:777-783.
31. Parameswaran R., Yu M., Lim M., Groffen J., Heisterkamp N. Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist. Leukemia 2011, 25:1314-1323.